口腔鳞癌患者唾液中生物学标记物研究进展

doi:10.3969/j.issn.1005-4979.2014.03.018

摘要/Abstract

关键词: 口腔鳞状细胞癌； , 唾液； , 生物学标记物

Key words: oral squamous cell carcinoma, saliva, biological markers

中图分类号:

R739.8

周燕平，雷荣昌. 口腔鳞癌患者唾液中生物学标记物研究进展[J]. 《口腔颌面外科杂志》, 2014, 24(3): 237-.

ZHOU Yan-ping, LEI Rong-chang. Recent Advances on Saliva Biomarkers in OSCC Patients[J]. 《Journal of Oral and Maxillofacial Surgery》, 2014, 24(3): 237-.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2014/V24/I3/237

[1] Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy[J]. J Dent Res, 2008, 87(1): 14-32.

[2] J emal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.

[3] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.

[4] Funk GF, Karnell LH, Robinson RA, et al. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report[J]. Head neck, 2002, 24(2): 165-180.

[5] Zimmermann BG，Wong DT. Salivary mRNA targets for cancer diagnostics[J]. Oral Oncology, 2008, 44(5): 425-429.

[6] Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma[J]. Clinl Cancer Res, 2008,14(1): 97-107.

[7] Brinkman BM, Wong DT. Disease mechanism and biomarkers of oral squamous cell carcinoma[J]. Curr Opin Oncol, 2006, 18(3): 228-233.

[8] Good DM, Thongboonkerd V, Novak J, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future[J]. J Proteome Res, 2007, 6(12): 4549-4555.

[9] Abdul-Wahab R, Shanaz M, Maissa T, et al. Study of serum and salivary levels of proinflammatory cytokines, potential biomarkers in the diagnosis of oral squamous cell carcinoma[J]. Acad J Cancer Res, 2011, 4 (2): 47-55.

[10] Schulz BL, Cooper-White J, Punyadeera CK. Saliva proteome research: current status and future outlook[J]. Crit Rev Biotechnol, 2012, 33(3):246-259.

[11] Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles[J]. Metabolomics, 2010, 6(1):78-95.

[12] de Almeida Pdel V, Grégio AM, Machado MA, et al. Saliva composition and functions: a comprehensive review[J]. J Contemp Dent Pract, 2008, 9(3): 72-80.

[13] Perez-Cornejo P, Gokhale A, Duran C, et al. Anoctamin 1 (Tmem16A) Ca2+-activated chloride channel stoichiometrically interacts with an ezrin-radixin-moesin network[J]. Proc Nat Acad Sci U S A, 2012, 109(26): 10376-10381.

[14] Wu JY, Yi C, Chung HR, et al. Potential biomarkers in saliva for oral squamous cell carcinoma[J]. Oral Oncol, 2010, 46(4): 226-231.

[15] Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral cancer biomarker discovery[J]. Clin Cancer Res, 2008, 14(19): 6246-6252.

[16] Liu J, Duan Y. Saliva:a potential media for disease diagnostics and monitoring[J]. Oral oncol,2012,48(7): 569-577.

[17] Zhong LP, Zhang CP, Zheng JW, et al. Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients[J]. Arch Oral Biol, 2007, 52(11): 1079-1087.

[18] Nagler R, Bahar G, Shpitzer T, et al. Concomitant analysis of salivary tumor markers-a new diagnostic tool for oral cancer[J]. Clin Cancer Res, 2006, 12(13): 3979-3984.

[19] Jou YJ, Lin CD, Lai CH, et al. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages[J]. Clin Chim Acta, 2011, 412(15-16): 1357-1365.

[20] Zhong LP, Zhang CP, Zheng JW, et al. Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients[J]. Arch Oral Biology, 2007, 52(11): 1079-1087.

[21] Franzmann EJ, Reategui EP, Pedroso F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer[J]. Cancer Epidemiol Biomarkers Prev, 2007, 16(7): 1348-1355.

[22] Rhodus NL, Ho V, Miller CS, et al. NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma[J]. Cancer Detect Prev, 2005, 29(1): 42-45.

[23] de Jong EP, Xie H, Onsongo G, et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions[J]. PLoS One, 2010, 5(6): e11148.

[24] Jou YJ, Lin CD, Lai CH, et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer[J]. Anal Chim Acta, 2010, 681(1-2): 41-48.

[25] Duffy SA, Taylor JM, Terrell JE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients[J]. Cancer, 2008, 113(4): 750-757.

[26] Sato J, Goto J, Murata T, et al. Changes in saliva interleukin-6 levels in patients with oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(3): 330-336.

[27] Nakahara Y, Shintani S, Mihara M, et al. Detection of p16 promoter methylation in the serum of oral cancer patients[J]. Intel J Oral Maxillofac Surg, 2006, 35(4): 362-365.

[28] Viet CT, Jordan RC, Schmidt BL. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer[J]. J Calif Dent Assoc, 2007, 35(12): 844-849.

[29] Langevin SM, Stone RA, Bunker CH, et al. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index[J]. Carcinogenesis, 2010, 31(5): 864-870.

[30] Viet CT, Schmidt BL. Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(12): 3603-3611.

[31] Franzmann EJ, Reategui EP, Pedroso F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer[J]. Cancer Epidemiol Biomarkers Prev, 2007, 16(7): 1348-1355.

[32] Guerrero-Preston R, Soudry E, Acero J, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva[J]. Cancer Prev Res, 2011, 4(7): 1061-1072.

[33] Oliveira LR, Ribeiro-Silva A, Costa JP, et al. Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2008, 106(5): 685-695.

[34] de Vicente JC, Olay S, Lequerica-Fernandez P, et al. Expression of Bcl-2 but not Bax has a prognostic significance in tongue carcinoma[J]. J Oral Pathol Med, 2006, 35(3): 140-145.

[35] Kato K, Kawashiri S, Yoshizawa K, et al. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas[J]. J Oral Pathology Med, 2008, 37(6): 364-371.

[36] Zhang M, Zhang P, Zhang C, et al. Prognostic significance of Bcl-2 and Bax protein expression in the patients with oral squamous cell carcinoma[J]. J Oral Pathology Med, 2009, 38(3): 307-313.

选择文件类型/文献管理软件名称

选择包含的内容